Skip to main content
. 2011 Jun 22;31(25):9254–9263. doi: 10.1523/JNEUROSCI.1543-11.2011

Figure 6.

Figure 6.

Effects of 0.1 μg/0.5 μl per side of atomoxetine in ACC (a), dPL (b), vmPFC (c), and OFC (d) on SSRT. The selective norepinephrine reuptake inhibitor atomoxetine (Ato) in dPL and OFC improved response inhibition decreasing SSRT, without significant effects on go-related measures (data not shown). The same drug infused into the ACC or vmPFC did not have any effect on SSRT and other stop-signal task variables. Veh, Vehicle. *p < 0.05 and **p < 0.01.